Proven Results
of Orilissa

ORILISSA is proven to relieve moderate to severe endometriosis pain

ORILISSA was studied in the largest endometriosis clinical trial program to date. It was studied in two 6-month clinical trials, including 1686 women aged 18-49 with moderate to severe endometriosis pain.

Study 1

The results below are from study #1 and show the measurements we took at 3 months for women taking the 150 mg dose once per day or the 200 mg dose twice per day vs placebo.

Percent of women who reported
REDUCED PERIOD PAIN*

ORILISSA 150 mg

ORILISSA 200 mg

Placebo

46%
76%
20%

Percent of women who reported REDUCED
PELVIC PAIN BETWEEN PERIODS*

ORILISSA 150 mg

ORILISSA 200 mg

Placebo

50%
55%
36%

*Based on 248 women taking ORILISSA 150 mg, 244 women taking ORILISSA 200 mg, and 373 women taking placebo.

Study 2

The results from study #2 measured at 3 months had similar outcomes to study #1:

Percent of women who reported
REDUCED PERIOD PAIN†

ORILISSA 150 mg

ORILISSA 200 mg

Placebo

43%
72%
23%

Percent of women who reported REDUCED
PELVIC PAIN BETWEEN PERIODS†

ORILISSA 150 mg

ORILISSA 200 mg

Placebo

50%
58%
37%

Percent of women who reported
reduced period pain†

150 mg=43%, 200 mg=72%, Placebo=23%

Percent of women who reported
reduced pelvic pain in between periods†

150 mg=50%, 200 mg=58%, Placebo=37%

†Based on 221 women taking ORILISSA 150 mg, 225 women taking ORILISSA 200 mg, and 353 women taking placebo.

 

In both studies ORILISSA was proven to reduce pain with sex in women who took the 200 mg dose.

These women achieved a reduction in their pain without increasing their use of painkillers.‡

‡Painkillers taken by women in the clinical studies included opioids (hydrocodone, codeine, or tramadol), naproxen, and acetaminophen.

ORILISSA starts working in the body to lower estrogen within 24 hours

While ORILISSA starts working in the body within 24 hours, pain relief will take longer. In the clinical studies, ORILISSA was proven to provide pain relief at 3 months.

""""

Got questions? We've got answers.